Goldman Sachs Group Inc. Has $39.03 Million Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Goldman Sachs Group Inc. lifted its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 1,038.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,401,899 shares of the medical equipment provider’s stock after buying an additional 2,191,002 shares during the period. Goldman Sachs Group Inc. owned about 5.46% of BioLife Solutions worth $39,031,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Millrace Asset Group Inc. increased its holdings in BioLife Solutions by 116.0% in the 4th quarter. Millrace Asset Group Inc. now owns 105,643 shares of the medical equipment provider’s stock worth $1,717,000 after purchasing an additional 56,726 shares in the last quarter. Granahan Investment Management LLC increased its stake in shares of BioLife Solutions by 22.8% in the fourth quarter. Granahan Investment Management LLC now owns 1,292,675 shares of the medical equipment provider’s stock valued at $21,006,000 after buying an additional 240,001 shares during the period. Roubaix Capital LLC increased its stake in shares of BioLife Solutions by 90.8% in the fourth quarter. Roubaix Capital LLC now owns 280,337 shares of the medical equipment provider’s stock valued at $4,555,000 after buying an additional 133,439 shares during the period. Barclays PLC increased its stake in shares of BioLife Solutions by 205.3% in the third quarter. Barclays PLC now owns 56,968 shares of the medical equipment provider’s stock valued at $787,000 after buying an additional 38,311 shares during the period. Finally, Meros Investment Management LP increased its stake in shares of BioLife Solutions by 14.7% in the third quarter. Meros Investment Management LP now owns 372,203 shares of the medical equipment provider’s stock valued at $5,140,000 after buying an additional 47,724 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on BLFS shares. Benchmark raised BioLife Solutions from a “neutral” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Monday, May 13th. StockNews.com raised BioLife Solutions to a “sell” rating in a research note on Friday, May 10th. Finally, Jefferies Financial Group assumed coverage on BioLife Solutions in a research note on Thursday, April 4th. They issued a “buy” rating and a $22.00 price target for the company. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to data from MarketBeat, BioLife Solutions currently has an average rating of “Moderate Buy” and an average target price of $23.67.

Insiders Place Their Bets

In other BioLife Solutions news, insider Sarah Aebersold sold 4,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $17.65, for a total value of $70,600.00. Following the transaction, the insider now owns 65,843 shares in the company, valued at $1,162,128.95. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CMO Todd Berard sold 10,000 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $15.67, for a total value of $156,700.00. Following the completion of the sale, the chief marketing officer now directly owns 129,644 shares of the company’s stock, valued at $2,031,521.48. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Sarah Aebersold sold 4,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $17.65, for a total value of $70,600.00. Following the completion of the sale, the insider now directly owns 65,843 shares of the company’s stock, valued at $1,162,128.95. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,209 shares of company stock worth $542,783. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Stock Up 0.8 %

Shares of BioLife Solutions stock opened at $21.00 on Friday. BioLife Solutions, Inc. has a one year low of $8.92 and a one year high of $23.85. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 1.77. The stock’s 50-day moving average is $19.69 and its 200 day moving average is $17.89. The firm has a market cap of $967.47 million, a price-to-earnings ratio of -14.79 and a beta of 1.80.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, May 9th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.06. The business had revenue of $31.73 million for the quarter, compared to analyst estimates of $29.30 million. BioLife Solutions had a negative return on equity of 12.89% and a negative net margin of 45.84%. During the same quarter in the prior year, the company earned ($0.27) earnings per share. Equities research analysts anticipate that BioLife Solutions, Inc. will post -0.44 EPS for the current year.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.